AVEO   $15.0  0.0 Market Closed

AVEO Pharmaceuticals Inc
Last Events:

2023-03-29 Signal in Stochastic changed from bullish weakening to bullish. The stochastic indicator is in overbought territory and it grows. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-03-29 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-03-29 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: main and signal line crossing.

2023-03-29 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-03-28 Signal in Stochastic changed from bullish weakening to bullish. The stochastic indicator is in overbought territory and it grows. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-03-28 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-03-28 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: main and signal line crossing.

2023-03-28 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.


Current temperature: 0.00
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 11.71
Target: 15.00
High with 50% probability: 18.29
Analyst Recommendations:
Number of estimates 4
Target Price Mean 15.00
Mean unverified/preliminary 15.00 / 15.00
Target Price Low / High 15.00 / 15.00
Median / STD DEV 15.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy Sell
rsi ActivelyBuy ActivelyBuy -
macd Sell Buy Sell
stoch Buy ActivelyBuy -
ma20 ActivelyBuy - -
ma50 ActivelyBuy - -
ma100 ActivelyBuy - -
Candlestick PatternDec. 30, 2022 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US0535883070
ceo Mr. Michael P. Bailey
Website https://www.aveooncology.com
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc.; CANbridge Life Sciences, Ltd.; Biogen Idec International GmbH; St. Vincent's Hospital Sydney Limited; and Kyowa Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.